BioCryst Pharmaceuticals (BCRX) reported a Q3 loss Monday of $0.07 per diluted share, narrowing from a loss of $0.19 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.06.

Revenue for the quarter ended Sept. 30 was $117.1 million, up from $86.7 million a year earlier.

Analysts surveyed by Capital IQ expected $114 million.

Cash, cash equivalents, restricted cash and investments as of Sept. 30 came in at $351.7 million, compared with $399.2 million a year earlier.

For 2024, the company said it expects revenue of $443 million to $448 million.

Analysts surveyed by Capital IQ expect $436.3 million.